Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)

The Lancet Oncology

Volumn 9, Issue 10, 2008, Pages 953-961

  Jenkins, Valerie A ^a   Ambroisine, Laurence M ^b   Atkins, Louise ^a   Cuzick, Jack ^b   Howell, Anthony ^c   Fallowfield, Lesley J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; PLACEBO; TAMOXIFEN;

ADULT; ARTICLE; ATTENTION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOCRINE DISEASE; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MEMORY; MENTAL DISEASE; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; TASK PERFORMANCE; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS, HORMONAL; ATTENTION; BREAST NEOPLASMS; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NITRILES; POSTMENOPAUSE; TRIAZOLES;

EID: 52749090040     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70207-9     Document Type: Article

References (30)

1. Cancer Research UK Breast Cancer Incidence Statistics (2008). http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/May (accessed May 7, 2008).
2. Cuzick J., Forbes J.F., and Howell A. Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 98 (2006) 643
3. Cuzick J. Chemoprevention of breast cancer. Breast Cancer 15 (2008) 10-16
4. Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99 (2007) 272-282
5. Freedman A.N., Graubard B.I., Rao S.R., McCaskill-Stevens W., Ballard-Barbash R., and Gail M.H. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95 (2003) 526-532
6. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
7. Jenkins V., Shilling V., Fallowfield L., Howell A., and Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13 (2004) 61-66
8. Bender C.M., Sereika S.M., Brufsky A.M., et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 14 (2007) 995-998
9. Castellon S.A., Ganz P.A., Bower J.E., Petersen L., and Greendale G.A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26 (2004) 955-969
10. Shilling V., Jenkins V., and Trapala I.S. The (mis)classification of chemo-fog-methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 95 (2006) 125-129
11. Jenkins V., Shilling V., Deutsch G., et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94 (2006) 828-834
12. Goldberg D., and Williams P. A user's guide to the General Health Questionnaire (1988), NFER-Nelson, Windsor
13. Broadbent D., Cooper P.F., FitzGerald P., and Parkes K.R. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 21 (1982) 1-16
14. Fallowfield L.J., Leaity S.K., Howell A., Benson S., and Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT- B. Breast Cancer Res Treat 55 (1999) 189-199
15. Mehnert A., Scherwath A., Schirmer L., et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 66 (2007) 108-118
16. Sawrie S.M., Chelune G.J., Naugle R.I., and Luders H.O. Empirical methods for assessing meaningful neuropsychological change following epilepsy surgery. J Int Neuropsychol Soc 2 (1996) 556-564
17. Taylor M., Brice J., and Buck N. Household Panel Survey users manual (1995), University of Essex, Colchester
18. Schagen S.B., Muller M.J., Boogerd W., Mellenbergh G.J., and van Dam F.S. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98 (2006) 1742-1745
19. Hermelink K., Untch M., Lux M.P., et al. Cognitive function during neoadjuvant chemotherapy for breast cancer. Results of a prospective, multicenter, longitudinal study. Cancer 109 (2007) 1905-1913
20. Shilling V., and Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11 (2007) 6-15
21. Palmer S.C., Kagee A., Coyne J.C., and DeMichele A. Experience of trauma, distress, and posttraumatic stress disorder among breast cancer patients. Psychosom Med 66 (2004) 258-264
22. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., and Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
23. Collins B., MacKenzie J., Stewart A., Bielajew C., and Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology (2008) 10.1002/pon.1379 published online June 12.
24. Yaffe K., Krueger K., Cummings S.R., et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 162 (2005) 683-690
25. Resnick S.M., Coker L.H., Maki P.M., Rapp S.R., Espeland M.A., and Shumaker S.A. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials 1 (2004) 440-450
26. Resnick S.M., Maki P.M., Rapp S.R., et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 91 (2006) 1802-1810
27. Norbury R., Craig M., Cutter W.J., Whitehead M., and Murphy D.G. Oestrogen: brain ageing, cognition and neuropsychiatric disorder. J Br Menopause Soc 10 (2004) 118-122
28. Fallowfield L., Fleissig A., Edwards R., et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19 (2001) 1885-1892
29. Basch E., Iasonos A., McDonough T., et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire based study. Lancet Oncol 7 (2007) 903-909
30. Vardy J., Wefel J.S., Ahles T., Tannock I.F., and Schagen S.B. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19 (2008) 623-629